Billie Heflin

Researcher

University of Arkansas for Medical Sciences

faculty

4 h-index 18 pubs 61 cited

Research Areas

Cancer Treatment and Pharmacology Cancer-related molecular mechanisms research Immune Response and Inflammation Phytochemicals and Antioxidant Activities CAR-T cell therapy research Acute Lymphoblastic Leukemia research Melanoma Research and Treatments Molecular Biology Techniques and Applications

Links

ORCID

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Billie Heflin's research focuses on understanding and targeting mechanisms of cancer cell survival and proliferation, with a particular emphasis on melanoma and leukemia. Heflin has investigated the potential of natural compounds, such as resveratrol and components of the Trametes versicolor mushroom, to exhibit anti-cancer activity in vitro and in organoid models. Studies have explored the role of specific genes, like S100b and EZH2, in regulating cancer cell apoptosis and immune response, utilizing techniques such as CRISPR/dCas9-KRAS-mediated suppression. Further work has examined the impact of EZH2 inhibition on CAR-T cell persistence and the susceptibility of acute lymphoblastic leukemia cells to microtubule depolymerization. Heflin's scholarship metrics include an h-index of 4, with 18 total publications and 61 total citations. Key collaborators include Megan R. Reed, Brian Koss, Alan J. Tackett, and Daniel Fil, all from the University of Arkansas for Medical Sciences, with whom Heflin has co-authored multiple publications.

Metrics

h-index: 4
Publications: 18
Citations: 61

Selected Publications

685 EZH2 inhibition impairs CD8+ CAR-T cell persistence (2025) DOI
691 ATF6 activation promotes ICB response in melanoma (2025) DOI
Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025) DOI
Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025) DOI
EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma (2025) DOI
1132 Enhancing melanoma therapy efficacy by protecting EZH2 activity in T cells (2024) DOI
538 ATF6 activation in melanoma promotes anti-tumor immunity and improves ICB therapy response (2024) DOI
Abstract 584: Synergistic action of ATF6 and EZH2 in sensing metabolic stress to boost anti-tumor immunity (2024) DOI
Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues (2023) DOI
536 EZH2 senses metabolic stress to restore MHC-I antigen presentation and ICB response in metastatic melanoma (2023) DOI
Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma (2023) DOI
Abstract LB041: EZH2 and ATF6 sense metabolic stress to balance MHC class I antigen presentation in melanoma (2023) DOI
CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells (2023) DOI
The mycelium of the Trametes versicolor synn. Coriolus versicolor (Turkey tail mushroom) exhibit anti-melanoma activity in vitro (2023) DOI
Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer (2022) DOI